Issue 02 2024

MicroPort[®]





MicroPort[®] Participates in Arab Health 2024, Completing the World's First Cross-Border 5G Simulated Tele-Surgery Verification

From 29 January to 1 February, the 49th edition of Arab Health took place in Dubai. This year, Arab Health, one of the world's largest comprehensive medical device and equipment exhibitions, attracted over 130,000 healthcare professionals from more than 190 countries and regions. MicroPort[®] and its associated companies participated in the exhibition, showcasing a range of innovative products and solutions in areas such as Coronary Intervention, Structural Heart Disease, Electrophysiology, Surgical Robotics, Extracorporeal Life Support, Urology, Endocrinology, and more.

Jonathan Chen, Chief International Business Officer of MicroPort[®], stated that, "This exhibition is a fantastic platform for showcasing MicroPort[®]'s diverse product line and powerful comprehensive medical innovation technology to a global audience. We engaged in meaningful discussions on cooperation with partners and leading medical institutions worldwide, establishing a solid foundation for future innovative collaborations. Furthermore, representatives from all MicroPort[®] business units held discussions on cooperation plans with over 250 potential customers and partners from various countries, including Morocco, India, Sri Lanka, and Saudi Arabia. MicroPort[®] is committed to further enhancing our global strategic plan for the long term. By leveraging the 'One MicroPort[®]' platform, we aim to maximize resource utilization, foster close collaborations with medical professionals globally, and dedicate ourselves to providing high-quality and comprehensive solutions to patients worldwide."

OND HEALTH



MicroPort[®] CRM announces the launch of GALI™ SonR[®] CRT-D and NAVIGO[™] 4LV left ventricular pacing leads in Japan

MicroPort* CRM, a pioneering company in the field of Cardiac Rhythm Management, headquartered in France, is pleased to announce the launch of the GALI[™] SonR[®] Cardiac Resynchronization Therapy and Defibrillation device (CRT-D) and NAVIGO[™] 4LV left ventricular pacing leads in Japan.

Kengo Kusano M.D., Director, Division of Arrhythmia and Electrophysiology, Department of Cardiovascular Medicine, the National Cerebral and Cardiovascular Center in Osaka, Japan, stated: "Around 3,700 patients in Japan are implanted by a CRT-D device annually. I am confident that MicroPort[®] CRM CRT-D system integrating cutting-edge algorithms with exceptional longevity, will contribute to ensuring the well-being and safety of our CRT-D patients".

"I am very impressed with the SonR technology. The use of a contractility sensor at the tip of the SonRtip[™] lead to automatically optimize cardiac resynchronization parameters, at rest and during exercise, is a very appealing solution. It is unique on the market, and its effectiveness is supported by solid clinical evidence." said Professor Morio Shoda M.D., Ph.D., Director and Professor, Clinical Research Division for Heart Rhythm Management, from Tokyo Women's Medical University.





VVED - DDDRV SN M00DXDDD



MICROPORT CRM S.R.L. - ITALY

SORIN



MicroPort[®] CRM Receives Approval for Its ENO[™] Pacing System in China

MicroPort* CRM's latest generation transvenous MR-conditional safe implantable pacemaker system has obtained approval in China.

The ENO[™] pacemaker family, including ENO[™], TEO[™], and OTO[™], features a compact volume of only 8cc and a projected longevity of up to 12 years. Comprising the ENO[™] pacemaker and Vega[™] pacing leads available in 3 lengths for clinical flexibility, this system is compatible with 1.5T/3T full-body MRI scans.

Featuring an AutoMRI[™] mode, the ENO[™] increases patients' safety and quality of life when undergoing an MRI examination. The pacemaker automatically switches to activate the MRI mode upon entering the MRI field and reverts to its initial settings following the exam. This technology allows patients to have repeated MRI scans within 10 days without further intervention, significantly improving workflow for both patients and medical staff.



As part of the "Clinical Investigation of ENO/TEO/OTO Pacing System (CAPRI) study conducted in 29 clinical centers worldwide, the ENO[™] system's safety and efficacy under MRI conditions was demonstrated . The research findings were published in the authoritative journal "European Radiology" in 2023.



MicroPort[®] CardioFlow Receives Approval for Its AnchorMan[®] LAAC System in China

AnchorMan[®] Left Atrial Appendage Closure System (AnchorMan[®] LAAC System), developed by CardioAdvent[®], an associated company of MicroPort[®] CardioFlow, recently obtained approval in China. Its companion product, the AnchorMan[®] LAA Access System, had previously been approved in October 2023.

Mr. Jeff Lindstrom, President of MicroPort^{*} CardioFlow, stated: "The innovative design of the AnchorMan^{*} LAAC System, with its rounded distal end and semi-closed structure, combines the advantages of both open and closed occluders. Its impressive clinical results are promising. The recent approval will enable the company to grow its business to the rapidly expanding and large patient-base segment of non-valve related structural heart disease. This expansion is anticipated to contribute to an increase in revenue scale and an optimization of operational efficiency".

Mr. Guoming Chen, Chairman of MicroPort[®] CardioFlow, stated: "This acquisition further deepens and expands MicroPort[®] CardioFlow's pipeline layout, which contributes to enhancing our global competitiveness. In the future, MicroPort[®] CardioFlow will strive to provide total solutions for structural heart diseases and is dedicated to providing high quality therapeutic solutions to patients and physicians across the globe".

MicroPort

MicroPort[®] MedBot[™] JV's R-ONE[®], the World's First Dual-Finger Grasp Mimic Vascular Intervention Robot, Receives Approval in China

Recently, R-ONE^{*} Vascular Intervention Robot (R-ONE^{*}), agented by Cathbot, a joint venture in China between MicroPort^{*} MedBot[™] and French company Robocath S.A.S, received approval in China. R-ONE^{*} is the world's first dual-finger grasp mimic vascular intervention robot that can reproduce manual operation.1 Its unique advantage in percutaneous coronary intervention is set to push cardiovascular interventional treatments into a new era of intelligence and precision.


The unique dual-finger grasp mimic technology of R-ONE^{*} can mimic the operator's hand gestures - 0 to 360 degrees rotating and moving continuously - making it easier to go through the complex lesion and tortuous vasculature. Furthermore, millimeter stepping enhances the precision of the device's positioning and the one-key locking/unlocking technology allows for secured access to the lesion during navigation. In Chinese clinical trials, R-ONE^{*} was used in a variety of challenging and complex cases, including large angle twisted vessels, diffuse long lesions, calcified lesions, and sub-total occlusions. The procedures conducted in these trials achieved a clinical and technological success rate of 100%.

With the progress of modern medicine, robotic treatment would enable better prognosis and postoperative quality of life.





MicroPort EverPace Receives CE MDR Certification for Its Latest Generation Columbus™ 3D EP Navigation System



MicroPort EverPace's latest generation Columbus[™] 3D EP Navigation System (Columbus[™]) has recently received CE MDR approval.

The 3D EP Navigation System represents a groundbreaking advancement in tachyarrhythmia treatment. This system merges hardware circuits, software systems, and core algorithms, resulting in a lengthy R&D cycle and high technical barriers. To fulfill clinical needs for high precision, stability, and reliability, the system places high expectations on its components and overall structure.

The latest generation Columbus[™] System includes two models. The EPE-SYS-2A, building upon its predecessor, adds an electrical positioning module and offers a new software interface more closely aligned with clinical needs. The Model EPE-SYS-1A features a completely new system architecture. It boasts enhanced signal processing capabilities, more electrode positioning and signal channels. Additionally, it integrates a direct catheter interface, electromagnetic positioning, ECG signal acquisition, and other modules, meeting higher precision clinical needs and providing more valuable information for clinical applications.

To date, the Columbus[™] system has successfully completed over 50,000 tachyarrhythmia treatments. In the future, MicroPort EverPace will remain committed to providing more high-quality and innovative products to the global market, ensuring comprehensive electrophysiology treatment and diagnostic solution for patients worldwide.

Investor Newsletter

For more information, please contact:

Martin Sun

Chief Financial Officer MicroPort Scientific Corporation **Tel:** (86)(21) 38954600 **Email:** ir@microport.com

Leanne Li

First Vice President of Board Secretary and Legal Affairs MicroPort Scientific Corporation **Tel:** (86)(21) 38954600 **Email: ir@microport.com**